Evidence map›Paper›PMID 36418864›Full record

ArticleNPJ vaccines2022

Author Correction: A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability.

Emily A Voigt, Alana Gerhardt, Derek Hanson, Madeleine F Jennewein, Peter Battisti, Sierra Reed, Jasneet Singh, Raodoh Mohamath, Julie Bakken, Samuel Beaver and 5 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Assembling the RNA therapeutics toolbox.Medical review (2021) · 2024
    Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Emily A VoigtRNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA. emily.voigt@aahi.org.ORCID http://orcid.org/0000-0001-5177-4063
Alana GerhardtProduct Development, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
Derek HansonRNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
Madeleine F JenneweinRNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.ORCID http://orcid.org/0000-0001-6633-7413
Peter BattistiRNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
Sierra ReedProduct Development, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
Jasneet SinghRNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
Raodoh MohamathFormulation Sciences, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
Julie BakkenRNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
Samuel BeaverRNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
Christopher PressProduct Development, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
Patrick Soon-ShiongImmunityBio, Inc, Culver City, CA, 90232, USA.
Christopher J PaddonAmyris, Inc, Emeryville, CA, 94608, USA.ORCID http://orcid.org/0000-0003-4182-2855
Christopher B FoxFormulation Sciences, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
Corey CasperRNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36418864
PMCPMC9684560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.